Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 6:5:Doc01.
doi: 10.3205/id000027. eCollection 2017.

Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany

Beate Grüner  1 , Petra Kern  2 , Benjamin Mayer  2 , Tilmann Gräter  3 , Andreas Hillenbrand  4 , Thomas E F Barth  5 , Rainer Muche  2 , Doris Henne-Bruns  4 , Wolfgang Kratzer  6 , Peter Kern  1
Affiliations

Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany

Beate Grüner et al. GMS Infect Dis. .

Abstract

Alveolar echinococcosis (AE) is the most Iethal human helminthic infection. The malignancy-like disease is rare, but morbidity and treatment costs are high. Objective of the study was to identify factors at baseline and during specific AE therapy influencing the long-term outcome of the disease. All patients with AE seen at the specialized treatment unit in Ulm between January 1992 and December 2011 were included in the analysis. The data of 312 patients were analyzed; 108 were diagnosed before 2000 (series A), 204 since 2000 (series B); 290 received specific AE treatment. Patients of series B were more often symptom-free at diagnosis (44.1% vs. 21.3%), had lower disease stages (50.0% vs. 34.2%) and more complete resections (57.7% vs. 20.0%), but higher rates of side effects and drug toxicity (54.1% vs. 40.8%). In series B, more patients remained relapse- or progression-free after 5 years (90.5% vs. 82.8%); after 10 years, the ratio of relapses converged (70.3% vs. 66.9%, p=0.0507). Relapses or progression occurred more often after incomplete surgery or long treatment pauses. The 5-year and 10-year survival rates were 96.9% and 90.6%, respectively, and 17% of the patients were cured. We observed a shift towards early diagnosis, earlier initiation of specific therapy and more complete resections after 2000. Although diagnosis and treatment of AE pose a challenge, with an individual interdisciplinary management 88.8% of the patients have a favorable outcome.

Keywords: Echinococcus multilocularis; alveolar echinococcosis; antiparasitic treatment; classification; risk factors; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Table 1
Table 1. Preconditions for structured treatment interruption (STI) for patients with non-resectable lesions and no evidence of extrahepatic lesions
Table 2
Table 2. Demographic data, symptoms and concomitant diseases at first diagnosis
Table 3
Table 3. Classification and PNM staging of alveolar echinococcosis
Table 4
Table 4. Patients with inactive lesionsa at diagnosis
Table 5
Table 5. Treatment of alveolar echinococcosis
Table 6
Table 6. Benzimidazole treatment and side-effects
Table 7
Table 7. State of BMZ therapy at the end of follow-up
Table 8
Table 8. Outcome of patients with alveolar echinococcosis
Table 9
Table 9. Cox proportional hazards regression analysis for covariates of relapse-free time
Figure 1
Figure 1. Relapse-free time after the start of specific treatment for AE (either BMZ treatment or first liver surgery; CI=Hall-Wellner confidence limits)
See this image and copyright information in PMC

References

    1. Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, Ammann RW, Vuitton DA, Kern P European Echinococcosis Registry. European echinococcosis registry: human alveolar echinococcosis, Europe, 1982-2000. Emerging Infect Dis. 2003 Mar;9(3):343–349. doi: 10.3201/eid0903.020341. - DOI - PMC - PubMed
    1. Pawłowski ZS, Eckert J, Vuitton DA, Ammann RW, Kern P, Craig PS, Dar KF, De Rosa F, Filice C, Gottstein B, Grimm F, Macpherson CNL, Sato N, Todorov T, Uchino J, von Sinner W, Wen H. Echinococosis in Humans: clinical aspects, diagnosis, and treatment. In: Eckert J, Gemmell MA, Meslin FX, Pawłowski ZS, editors. WHO/OIE Manual on Echinococcosis in Humans and Animals: a Public Health Problem of Global Concern. Paris: OIE, WHO; 2001. pp. 20–72. Available from: http://apps.who.int/iris/bitstream/10665/42427/1/929044522X.pdf.
    1. Eckert J, Deplazes P, Kern P. Alveolar echinococcosis (Echinococcus multilocularis): and neotropical forms of echinococcosis (Echinococcus vogeli and Echinococcus oligarthrus) In: Palmer SR, Soulsby EJ, Torgerson P, Brown DW, editors. Oxford Textbook of Zoonoses: Biology, Clinical Practice, and Public Health Control. 2nd ed. New York: Oxford University Press; 2011. pp. 669–699. - DOI
    1. Ammann RW, Renner EC, Gottstein B, Grimm F, Eckert J, Renner EL Swiss Echinococcosis Study Group. Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001) J Hepatol. 2004 Oct;41(4):551–559. doi: 10.1016/j.jhep.2004.06.015. - DOI - PubMed
    1. Torgerson PR, Schweiger A, Deplazes P, Pohar M, Reichen J, Ammann RW, Tarr PE, Halkik N, Müllhaupt B. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol. 2008 Jul;49(1):72–77. doi: 10.1016/j.jhep.2008.03.023. - DOI - PubMed

LinkOut - more resources